Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric oncology group/children's cancer group phase II study 9457 - A report from the children's oncology group Academic Article uri icon

Overview

MeSH Major

  • Amifostine
  • Bone Neoplasms
  • Cyclophosphamide
  • Sarcoma, Ewing
  • Topotecan

abstract

  • Topotecan had limited activity in patients with Ewing sarcoma or PNET metastatic at diagnosis. The topotecan-cyclophosphamide combination was active. Amifostine was not myeloprotective. Overall results showed no improvement compared with previous studies.

publication date

  • January 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.02.1717

PubMed ID

  • 16382125

Additional Document Info

start page

  • 152

end page

  • 9

volume

  • 24

number

  • 1